Filing Flows › Kymera Therapeutics (KYMR) › Q4 2025
Kymera Therapeutics (KYMR) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Kymera Therapeutics (KYMR) reported revenue of $2.9M for the fourth quarter 2025 (Q4 2025), -61% from a year earlier and +4% from the quarter before.
Kymera Therapeutics, Q4 2025: revenue $2.9M (-61% year over year), net loss $87.0M, operating cash flow −$66.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | +4% | -61% |
| Operating profit | −$97.9M | — | — |
| Net earnings | −$87.0M | — | — |
| Operating cash flow | −$66.7M | — | — |
What changed
Revenue was $2.9M in Q4 2025, down 61% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $97.9M, an operating margin of -3411.0%. Total costs grew 14% against a revenue fall of 61%. The quarter ended with a net loss of $87.0M, wider than the previous quarter's $82.2M loss.
Operating cash flow was −$66.7M. Non-cash charges added back $2.0M of depreciation and amortization and $14.5M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $106K exceeded it, leaving free cash flow of −$66.9M.
Questions
What was Kymera Therapeutics' revenue in the fourth quarter 2025?
Kymera Therapeutics (KYMR) reported revenue of $2.9M for the fourth quarter 2025 (Q4 2025), -61% from a year earlier and +4% from the quarter before.